About Neocannbio
Neocannbio is a company based in Seoul (South Korea) founded in 2021. Neocannbio has raised $10.9 million across 2 funding rounds from investors including KT&G, Medytox and QUAD Investment Management. Neocannbio operates in a competitive market with competitors including ZYUS Life Sciences, Sanity Group, Terraflos, Avicanna and Little Green Pharma, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Neocannbio Co., Ltd.
-
Annual Revenue
$81.82 K (USD)372as on Dec 31, 2022
-
Net Profit
-$209.55 K (USD)-335as on Dec 31, 2022
-
EBITDA
-$209.55 K (USD)-335as on Dec 31, 2022
-
Total Equity Funding
$10.9 M (USD)
in 2 rounds
-
Latest Funding Round
$7.47 M (USD), Series B
Sep 26, 2023
-
Investors
KT&G
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neocannbio
Neocannbio has successfully raised a total of $10.9M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $7.47 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $7.5M
-
First Round
First Round
(26 Jul 2022)
- Investors Count 9
Investors in Neocannbio
Neocannbio has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include KT&G, Medytox and QUAD Investment Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neocannbio
Financial Statements - Neocannbio
Neocannbio Comparisons
Competitors of Neocannbio
Neocannbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZYUS Life Sciences, Sanity Group, Terraflos, Avicanna and Little Green Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cannabis-derived therapeutics for multiple indications are developed.
|
|
| domain | founded_year | HQ Location |
Developer of cannabinoid-based pharmaceuticals and well-being products
|
|
| domain | founded_year | HQ Location |
Medical cannabis products are provided based on GMP processes.
|
|
| domain | founded_year | HQ Location |
Plant-derived cannabinoid products are developed for medical and consumer uses.
|
|
| domain | founded_year | HQ Location |
Manufacturer of medicinal cannabis for therapeutic use
|
|
| domain | founded_year | HQ Location |
Developer of medical cannabis products
|
Frequently Asked Questions about Neocannbio
Neocannbio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Neocannbio is headquartered in Seoul, South Korea.
Jungyeob Ham is the current CEO of Neocannbio.
Neocannbio is a funded company, having raised a total of $10.9M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.43M, raised on Jul 26, 2022.
Annual revenue of Neocannbio is $81.82K as on Dec 31, 2022.
Neocannbio was founded in 2021 in Seoul, South Korea, within the biotechnology sector focused on cannabinoids. Cannabinoid-based drugs are developed using intelligent delivery systems and synergistic effects to enhance efficacy. A comprehensive cannabinoid library is built from hemp to support efficacy discoveries, assay services, and raw material production. Core technologies encompass microwave processing for high-purity CBD and metabolic engineering for scalable manufacturing.
Neocannbio's top competitors include Avicanna, ZYUS Life Sciences and IMCannabis.
Neocannbio has 9 investors. Key investors include KT&G, Medytox, QUAD Investment Management, Bilanx, and Donghoon Investment.